HOBOKEN, N.J.--(BUSINESS WIRE)--Octapharma USA has appointed Richard E. Walters, Jr. as Vice President of Commercial Development, assuming immediate responsibility for all U.S. product marketing, commercial development and coordination with global portfolio development initiatives.
Walters is a senior executive with more than 30 years of industry leadership experience, including eight years with CSL Behring where he served as Vice President of U.S. Sales and Corporate Accounts for the global biotherapeutics company. Most recently, he was with General Medical Services of Summit, N.J., serving as Vice President of Sales & Marketing responsible for the management and commercial operations for two new companies operating in the retina therapy marketplace.
“We are fortunate to have Rich Walters join our senior management team,” said Octapharma USA President Flemming Nielsen. “Rich has extensive U.S. and international experience with particular expertise in marketing, management and business development. Rich will play a vital role with Octapharma USA as we continue to grow our product portfolio in the U.S. with the goal of providing patients with life-enhancing and life-saving therapies.”
Earlier in his career, Walters held biopharmaceutical marketing and sales leadership positions with Sanofi-Aventis and Rhône-Poulenc Rorer, which later became part of Aventis. He earned a B.A. in Marketing from Ursinus College and an M.B.A., Marketing from Saint Joseph’s University.
About the Octapharma Group
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell lines. Octapharma employs approximately 7,100 people worldwide to support the treatment of patients in over 113 countries with products across the following therapeutic areas: Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.